Treace Medical Concepts, Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
Treace Medical Concepts, Inc. (TMCI) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $6.46 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-07
- Treace Medical Concepts, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $6.46M, a 32.52% decline year-over-year.
- Treace Medical Concepts, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $8.03M, a 7.58% decline year-over-year.
- Treace Medical Concepts, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $8.00M, a 1.24% increase year-over-year.
- Treace Medical Concepts, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $9.58M, a 42.09% increase year-over-year.
- Treace Medical Concepts, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $33.82M, a 10.52% increase from fiscal 2024.
- Treace Medical Concepts, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $30.60M, a 76.25% increase from fiscal 2023.
- Treace Medical Concepts, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $17.36M, a 114.07% increase from fiscal 2022.
- Treace Medical Concepts, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $8.11M, a 137.93% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.46M 10-Q · filed 2026-08-07 | $14.50M derived: sum of 2 quarters · filed 2026-08-07 | ||
| 2026-03-31 | $8.03M 10-Q · filed 2026-08-07 | |||
| 2025-12-31 | $33.82M 10-K · filed 2026-02-27 | |||
| 2025-09-30 | $8.00M 10-Q · filed 2025-11-06 | $17.57M derived: sum of 2 quarters · filed 2026-08-07 | $26.27M derived: sum of 3 quarters · filed 2026-08-07 | |
| 2025-06-30 | $9.58M 10-Q · filed 2026-08-07 | $18.27M derived: sum of 2 quarters · filed 2026-08-07 | ||
| 2025-03-31 | $8.69M 10-Q · filed 2026-08-07 | |||
| 2024-12-31 | $30.60M 10-K · filed 2026-02-27 | |||
| 2024-09-30 | $7.90M 10-Q · filed 2025-11-06 | $14.64M derived: sum of 2 quarters · filed 2025-11-06 | $22.05M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $6.74M 10-Q · filed 2025-11-06 | $14.15M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $7.41M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $17.36M 10-K · filed 2026-02-27 | |||
| 2023-09-30 | $5.19M 10-Q · filed 2024-11-05 | $8.79M derived: sum of 2 quarters · filed 2024-11-05 | $11.48M derived: sum of 3 quarters · filed 2024-11-05 | |
| 2023-06-30 | $3.60M 10-Q · filed 2024-11-05 | $6.29M derived: sum of 2 quarters · filed 2024-11-05 | ||
| 2023-03-31 | $2.69M 10-Q · filed 2024-11-05 | |||
| 2022-12-31 | $8.11M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $2.27M 10-Q · filed 2023-11-09 | $4.23M derived: sum of 2 quarters · filed 2023-11-09 | $5.64M derived: sum of 3 quarters · filed 2023-11-09 | $6.93M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $1.96M 10-Q · filed 2023-11-09 | $3.37M derived: sum of 2 quarters · filed 2023-11-09 | $4.67M derived: sum of 3 quarters · filed 2024-02-27 | $5.50M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $1.41M 10-Q · filed 2023-11-09 | $2.70M derived: sum of 2 quarters · filed 2024-02-27 | $3.54M derived: sum of 3 quarters · filed 2024-02-27 | $4.42M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $2.13M derived: sum of 2 quarters · filed 2024-02-27 | $3.01M derived: sum of 3 quarters · filed 2024-02-27 | $3.41M 10-K · filed 2024-02-27 |
| 2021-09-30 | $839.00K 10-Q · filed 2022-11-09 | $1.71M derived: sum of 2 quarters · filed 2022-11-09 | $2.12M 10-Q · filed 2021-11-04 | $2.45M derived: sum of 4 quarters · filed 2023-03-08 |
| 2021-06-30 | $875.00K 10-Q · filed 2022-11-09 | $1.28M 10-Q · filed 2021-08-05 | $1.61M derived: sum of 3 quarters · filed 2023-03-08 | $1.74M derived: sum of 4 quarters · filed 2023-03-08 |
| 2021-03-31 | $402.00K 10-Q · filed 2022-11-09 | $739.00K derived: sum of 2 quarters · filed 2023-03-08 | $864.00K derived: sum of 3 quarters · filed 2023-03-08 | $1.11M derived: sum of 4 quarters · filed 2023-03-08 |
| 2020-12-31 | $337.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $462.00K derived: sum of 2 quarters · filed 2023-03-08 | $710.00K derived: sum of 3 quarters · filed 2023-03-08 | $919.00K 10-K · filed 2023-03-08 |
| 2020-09-30 | $125.00K 10-Q · filed 2021-11-04 | $373.00K derived: sum of 2 quarters · filed 2021-11-04 | $582.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $248.00K 10-Q · filed 2021-08-05 | $457.00K 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $209.00K 10-Q · filed 2021-05-25 | |||
| 2019-12-31 | $815.00K 10-K · filed 2022-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |